\
&
Contact us
Published on | 4 years ago
Programmes ICTThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
Communication technologies like 5G and 6G are fundamental aspects for the digital transformation of Europe. Plenty of funding opportunities will therefore be present in Horizon Europe. Quite some of the coordination of these topics will happen by the European Partnership for Smart Networks and Services.
This Smart Networks and Services partnership aims to strengthen Europe’s scientific and industrial leadership. It will help to
Quite some existing organisations have put their shoulders under this initiative (that will launch as an Institutionalized Partnership - Art185/7): 5G-IA, Networld2020, AIOTI, Cispe.cloud, NESSI...
The priorities of the partnership are stated in the Strategic Research and Innovation Agenda 2021-27: "smart networks in het context of NGI". The identified key areas for the EU R&I community that are relevant for the future of communications technology are the following:
The majority of funding opportunities for 5G and 6G is expected to be published directly by the Work Programme of the European Partnership for Smart Networks and Services. However, in the draft WP of cluster 4, 5G and 6G are explicitly mentioned in the following topics:
It is always interesting to check out which projects were funded in the past years on the topics related to 4G and 5G. Attached to this article, you can find an overview document that our Swiss colleagues (euresearch) have put together and were so kind to share.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.